<DOC>
	<DOCNO>NCT02114034</DOCNO>
	<brief_summary>The purpose prospective study : - identify cluster analysis main phenotype severe asthma factor involve severity , - determine clinical functional outcome , - identify factor associate severe asthma childhood adulthood .</brief_summary>
	<brief_title>Cohort Analysis Clinical Biological Severe Childhood Asthma</brief_title>
	<detailed_description>Severe asthma involve 5 % asthmatic child associate high impact hospitalization , absenteeism quality life . Although knowledge progress substantial way last ten year , number unresolved question persist particular regard contribute factor outcomes early childhood adulthood . After parental agreement follow element collect inclusion : clinical environmental data , pulmonary function , allergy test data ( skin prick test specific IgE ) , blood serum sample biobank ( DNA / SERUM ) . In restricted number child extensive work perform may include flexible bronchoscopy , bronchial brushing bronchoalveolar lavage . The follow-up perform every 6 month within framework usual care include collection clinical data pulmonary function test . The allergic status do 6-7 year , 12 year 18 year . In group child non-severe asthma , follow-up annual collection clinical data pulmonary function test .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<criteria>Children severe asthma : Child age 3 12 year Asthmatic child , despite treatment combination inhale corticosteroid ( least 800 mcg / day equivalent Beclomethasone ) bronchodilator longacting properly take daily leukotriene short act nebulized bronchodilator ( inhaler technique compliance verify ) present one criterion following : Persistence symptom chronic use bronchodilator short duration action least three time week least 3 month exacerbation previous year : least one care unit admission continue resuscitation least two hospitalization acute severe asthma require IV therapy least 2 course oral corticosteroid exacerbation post BD FEV &lt; 80 % UARS post BD &gt; 150 % predicted Signature consent holder ( ) parental authority Particular case patient treat Xolair® : Patients currently receive Xolair® meet severity criterion asthma , describe , start treatment Xolair® includable . Children nonsevere asthma : Inclusion Criteria Child age 3 12 year Controlled without treatment low dos inhale corticosteroid ( &lt; 500 mg / day beclometasone equivalent ) asthma Child normal EFR ( Child 4 year ) Child severe exacerbation ( assessed take oral corticosteroid ) previous year Child admit previous year asthma . Signature consent holder ( ) parental authority Child bronchopulmonary dysplasia Child severe sequelae viral infection Refusal child parent Data collection research follow patient : test carry 3 month prior inclusion use Blood sample DNA extraction biobank : young child , sample least 4 5 ml dry tube serum 6 ml least DNA . These sample store room temperature , transport within 48 hour biological resource ( CRB ) Necker E , fa , t Malades .</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Severe asthma ,</keyword>
	<keyword>child ,</keyword>
	<keyword>outcome ,</keyword>
</DOC>